Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT: Aspirin for Prevention of Recurrent Preterm Birth
NCT06980025Phase 3Recruiting
- Sponsor
- George Washington University Biostatistics Center
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in preterm birth (2 arms), sponsored by George Washington University Biostatistics Center. Primary endpoint: Rate of recurrent preterm delivery or fetal death prior to 35 weeks 0 days gestation. Started Jul 2025; status: recruiting.
02
Drugs
aspirin
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT06980025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980025.